Khassouk and National Disability Insurance Agency (NDIS) [2024] ARTA 233 (20 November 2024)
Applicant/s: Sabriah Khassouk
Respondent: National Disability Insurance Agency
Tribunal Number: 2022/9255
Tribunal:General Member L Proske
Place:Adelaide
Date:20 November 2024
Decision:The Tribunal affirms the decision under review.
..................[SGND]......................................................
General Member L Proske
Catchwords
NATIONAL DISABLITY INSURANCE SCHEME – access to the scheme – disability requirements – permanence– decision under review affirmed
Legislation
Administrative Review Tribunal Act 2024 (Cth)
National Disability Insurance Scheme Act 2013 (Cth)
National Disability Insurance Scheme (Getting the NDIS Back on Track No.1) Act 2024 (Cth)
National Disability Insurance Scheme (Becoming a Participant) Rules 2016 (Cth)Cases
Mulligan v National Disability Insurance Agency [2015] FCA 544
National Disability Insurance Agency v Davis [2022] FCA 1002
Re Drake and Minister for Immigration and Ethnic Affairs (1979) 46 FLR 409Statement of Reasons
The Applicant (Ms Khassouk) has applied to the Tribunal for review of a decision made by the National Disability Insurance Agency (Respondent) on 14 October 2022. That decision confirmed an earlier decision made by the Respondent that Ms Khassouk did not meet the access criteria for the National Disability Insurance Scheme (NDIS), as prescribed under the National Disability Insurance Scheme Act 2013 (Cth) (NDIS Act).[1]
[1] All sections referred to in these reasons for decision, including in the footnotes, are sections of the National Disability Insurance Scheme Act 2013 (Cth) (NDIS Act), unless otherwise stated.
BACKGROUND AND JURISDICTION
Ms Khassouk made an access request to the Respondent to become a participant of the NDIS. On 23 August 2022, a delegate of the Chief Executive Officer (CEO) of the Respondent determined that Ms Khassouk did not meet the access criteria for the NDIS (original decision).[2] On 21 September 2022, Ms Khassouk requested that the original decision be reviewed by a reviewer.[3]
[2] Exhibit 1 (E1), T12, 121.
[3] E1, 128.
On 14 October 2022, a reviewer confirmed the original decision that Ms Khassouk did not meet the access criteria for the NDIS (internal review decision).[4] On 10 November 2022, Ms Khassouk made an application to the Tribunal for review of the internal review decision.[5] The Tribunal has jurisdiction to review the internal review decision under s 103(1), in combination with s 12 of the Administrative Review Tribunal Act 1975 (Cth) (ART Act).
[4] E1, 22.
[5] E1, 1.
LEGISLATION AND POLICY
Ms Khassouk must meet the access criteria in s 21(1) to become a participant of the NDIS. In summary, s 21(1) provides that a person meets the access criteria if they meet the age requirements in s 22; the residence requirements in s 23; and either the disability requirements in s 24 or the early intervention requirements in s 25.
There is no dispute between the parties, and the Tribunal is similarly satisfied on the evidence before it, that the Applicant meets the age and residence requirements in ss 22…
Keep reading for free
Create a free CaseChat account to read Khassouk and National Disability Insurance Agency (NDIS) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2024] ARTA 233
- Decision Date
CaseChat Overview and Summary
The central legal issue before the Tribunal was whether Ms Khassouk met the access criteria for the NDIS as outlined in the NDIS Act. Specifically, the Tribunal had to determine if Ms Khassouk's impairments met either the disability requirements in section 24 or the early intervention requirements in section 25 of the Act. Ms Khassouk argued that her conditions, including Sjogren’s Syndrome, Systematic Lupus Erythematosus (SLE), Secondary Hemophagocytic Lymphohistiocytosis (HLH), osteoporosis, bone fractures, anaemia, and recurrent urinary tract infections (UTIs), satisfied the criteria for NDIS participation. The NDIS contested this, asserting that Ms Khassouk's conditions were not permanent and did not sufficiently impair her functional capacity.
The Tribunal reviewed the legislative requirements and the evidence presented. It found that while Ms Khassouk had a disability attributable to certain conditions, these conditions were not deemed permanent or likely to be permanent. The Tribunal also concluded that Ms Khassouk did not demonstrate a substantial reduction in functional capacity in the activities specified in the Act as a result of these impairments. Consequently, the Tribunal upheld the internal review decision, affirming that Ms Khassouk did not meet the access criteria for the NDIS.
The Tribunal’s decision was based on the evidence and the interpretation of the relevant sections of the NDIS Act, concluding that Ms Khassouk’s impairments did not meet the required permanence and functional capacity criteria. The Tribunal affirmed the NDIS’s decision that Ms Khassouk was not eligible for participation in the scheme.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
The Respondent filed submissions on 11 October 2024, to the effect that pursuant to s 126 of the Amending Act, amendments made by the Amending Act to ss 24 and 25 of the NDIS Act apply to a person who makes an access request on or after 3 October 2024; and that in circumstances where Ms Khassouk’s access request was made before 3 October 2024, it should be determined in accordance with the NDIS Act and NDIS Rules as they existed before the commencement of the Amending Act on 3 October 2024. The Tribunal agrees with those submissions. CONSIDERATION The issue for determination by the Tribunal is whether the Applicant meets the disability requirements in s 24 or the early intervention requirements in s 25. Ms Khassouk is seeking access to the NDIS on the basis of impairments arising from Sjogren’s Syndrome, Systematic Lupus Erythematosus (SLE), Secondary Hemophagocytic Lymphohistiocytosis (HLH), osteoporosis, bone fractures, anaemia and recurrent urinary tract infections (UTIs).[8] Prior to the hearing, Ms Khassouk confirmed she does not rely on impairments arising from rheumatoid arthritis, or impairments to which a psychosocial disability is attributable, for access to the NDIS.[9] [8] E1, 226-228; Ms Khassouk’s Reply to the Respondent’s Statement of Facts, Issues and Contentions (Ms Khassouk’s Reply), 1.[9] Ms Khassouk’s Reply, 1; and an email sent by Ms Haj to the Tribunal and the Respondent dated 15 August 2023. The Respondent accepts Ms Khassouk has a disability that is attributable to physical impairments arising from Sjogren’s Syndrome, HLH and SLE; but does not accept she has a disability that is attributable to impairments arising from UTIs, osteoporosis, bone fractures or anaemia.[10] The Respondent does not accept that Ms Khassouk’s physical impairments are, or are likely to be, permanent.[11] The Respondent also contends the Tribunal ought to find Ms Khassouk does not have substantially reduced functional capacity for any of the relative activities as a result of any permanent impairment.[12] [10] Respondent’s Statement of Facts, Issues and Contentions (RSFIC), [23]-[24].[11] E1, [26], [73].[12] RSFIC, [36]. Ms Khassouk has a long and complex medical history. In a letter dated 12 July 2016, Dr Griff Richards (Dr Richards), rheumatologist, reported that Ms Khassouk had an onset of cutaneous polyarteritis nodosa in 2000 with fever and neutropenia.[13] Dr Richards reported Ms Khassouk had had no recurrence of that condition, despite having ceased Imuran and Plaquenil therapy at least 2 years prior; and with respect to other medical issues noted Ms Khassouk was on long term narcotic medication including Endone and Oxycontin.[14] On 18 January 2018, Dr Richards reported that Ms Khassouk was previously on long-term low dose corticosteroid therapy as well as Imuran that seems to control her autoimmune disease, that at that time was diagnosed as cutaneous polyarthritis nodosa.[15] He further reported that recent immunological tests were consistent with SLE, she was strongly positive in regard to her DNA antibody and her pancytopenia is secondary to her autoimmune disease.[16] Dr Richards began treating Ms Khassouk with immunosuppressive treatment which included Imuran and Prednisone, and reported she would continue with vitamin D therapy and take oxycontin for her chronic pain syndrome.[17][13] E1, 9.[14] E1, 9.[15] E1, 476.[16] E1, 476.[17] E1, 476.